

[ Wed, Oct 02nd 2024
] - WOPRAI


[ Mon, Aug 12th 2024
] - WOPRAI


[ Wed, Jul 31st 2024
] - WOPRAI

[ Thu, Jul 25th 2024
] - WOPRAI

[ Wed, Jun 26th 2024
] - WOPRAI

[ Thu, May 16th 2024
] - WOPRAI

[ Tue, May 14th 2024
] - WOPRAI

[ Tue, Apr 30th 2024
] - WOPRAI

[ Mon, Apr 22nd 2024
] - WOPRAI

[ Thu, Apr 04th 2024
] - WOPRAI


[ Wed, Mar 06th 2024
] - WOPRAI

[ Thu, Aug 10th 2023
] - WOPRAI

[ Thu, May 18th 2023
] - WOPRAI

[ Mon, Apr 24th 2023
] - WOPRAI

[ Wed, Mar 22nd 2023
] - WOPRAI

[ Fri, Mar 10th 2023
] - WOPRAI

[ Tue, Feb 28th 2023
] - WOPRAI

[ Sun, Feb 05th 2023
] - WOPRAI

[ Tue, Jan 03rd 2023
] - WOPRAI

[ Mon, Dec 12th 2022
] - WOPRAI

[ Thu, Nov 17th 2022
] - WOPRAI

[ Mon, Nov 07th 2022
] - WOPRAI


[ Wed, Jun 22nd 2022
] - WOPRAI

[ Wed, Feb 16th 2022
] - WOPRAI

[ Thu, Oct 08th 2020
] - WOPRAI

[ Tue, Jul 23rd 2019
] - WOPRAI
Mark Massaro Maintained (ADPT) at Strong Buy with Increased Target to $8 on, Oct 2nd, 2024
Mark Massaro of BTIG, Maintained "Adaptive Biotechnologies Corporation" (ADPT) at Strong Buy with Increased Target from $7 to $8 on, Oct 2nd, 2024.
Mark has made no other calls on ADPT in the last 4 months.
There is 1 other peer that has a rating on ADPT. Out of the 1 peers that are also analyzing ADPT, 0 agree with Mark's Rating of Hold.
This is the rating of the analyst that currently disagrees with Mark
- Rachel Vatnsdal of "JP Morgan" Maintained at Buy with Increased Target to $6 on, Friday, August 2nd, 2024